SCHEMBL14010409

SCHEMBL14010409

CC(C)(C)[Si](C)(C)O[C@H]1CC[C@H](NC(=O)OCc2ccccc2)C1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
GAA P10253 1/20 0.55
TSHR P16473 1/20 0.53
TLR4 O00206 1/20 0.47
EPHX1 P07099 1/20 0.47
CPB1 P15086 2/20 0.46
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
CTSK P43235 1/20 0.46
DPP4 P27487 3/20 0.44
DPP7 Q9UHL4 3/20 0.44
KCNH2 Q12809 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
ACHE P22303 1/20 0.44
HSD11B1 P28845 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5011213 1.00 ALDH1A1 (0.55) ALDH1A1GAATSHRTLR4EPHX1
SCHEMBL2992037 0.94 ALDH1A1 (0.62) ALDH1A1GAATSHREPHX1CPB1
SCHEMBL2992039 0.94 ALDH1A1 (0.62) ALDH1A1GAATSHREPHX1CPB1
SCHEMBL5007203 0.94 ALDH1A1 (0.62) ALDH1A1GAATSHREPHX1CPB1
SCHEMBL9471139 0.92 ALDH1A1 (0.52) ALDH1A1GAATSHRTLR4EPHX1
SCHEMBL328917 0.88 EPHX1 (0.57) ALDH1A1GAATSHREPHX1CPB1
SCHEMBL19863575 0.86 CPB1 (0.48) ALDH1A1GAATSHREPHX1CPB1
SCHEMBL20991956 0.86 CPB1 (0.48) ALDH1A1GAATSHREPHX1CPB1
SCHEMBL19456282 0.84 CPB1 (0.47) ALDH1A1GAATSHREPHX1CPB1
SCHEMBL29595972 0.84 CPB1 (0.47) ALDH1A1GAATSHREPHX1CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452893-B2 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists MERCK & CO., INC. (US) 2008-11-18 US disclosed
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients MERCK & CO., INC. (US) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients GRIN2B, GRIN3A, GRIN2A ALDH1A1 636/4885GAA 171/4885TSHR 2936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.